Abstract
Despite major advances in cancer therapeutics, the prognosis for lung cancer patients is still poor and the median survival for patients presenting with advanced non-small cell lung cancer (NSCLC) is only 8-10 months. Angiogenesis is an important biological process and a relatively early event during lung cancer pathogenesis. Anti-angiogenic agents are used in treating patients with NSCLC, and their molecular biomarkers are also being assessed to predict response. A better understanding of the biology of angiogenesis in NSCLC may reveal new targets for treating this malignancy. In this article, we review the expression and prognostic impact of the angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor, in NSCLC.
Copyright © 2012. Published by Elsevier Ireland Ltd.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Biomarkers, Tumor / genetics
-
Biomarkers, Tumor / metabolism
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / genetics*
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Fibroblast Growth Factor 2 / genetics*
-
Fibroblast Growth Factor 2 / metabolism
-
Gene Expression Regulation, Neoplastic* / drug effects
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / metabolism
-
Neovascularization, Pathologic / genetics
-
Neovascularization, Pathologic / metabolism
-
Prognosis
-
Signal Transduction / drug effects
-
Vascular Endothelial Growth Factor A / genetics*
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Angiogenesis Inhibitors
-
Biomarkers, Tumor
-
Vascular Endothelial Growth Factor A
-
Fibroblast Growth Factor 2